Dr. Braghiroli on Individualization of Treatment in CRC

Maria Ignez Braghiroli, MD
Published: Wednesday, Oct 12, 2016



Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses the ways in which treatment can be individualized for patients with colorectal cancer (CRC) depending on the mutations they may harbor.

For example, explains Braghiroli, patients with RAS-mutated CRC do not seem to respond positively to anti-EGFR medications. Moreover, patients with BRAF-mutated disease generally tend to have a worse prognosis.

Multiple studies have focused on the respective efficacies of BRAF and MEK inhibitors, MEK inhibitors, as well as combinations of these agents. Overall, says Braghiroli, these various subgroups of patients will require individualized treatment approaches.


Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses the ways in which treatment can be individualized for patients with colorectal cancer (CRC) depending on the mutations they may harbor.

For example, explains Braghiroli, patients with RAS-mutated CRC do not seem to respond positively to anti-EGFR medications. Moreover, patients with BRAF-mutated disease generally tend to have a worse prognosis.

Multiple studies have focused on the respective efficacies of BRAF and MEK inhibitors, MEK inhibitors, as well as combinations of these agents. Overall, says Braghiroli, these various subgroups of patients will require individualized treatment approaches.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x